Latest news with #Carlsmed
Axios
2 days ago
- Business
- Axios
DOGE makes its way into biotech IPO filings
DOGE cuts are leading to new warnings in filings from biotech and health-care companies looking to IPO stateside. The big picture: Uncertainty is a deal killer. According to data from Renaissance Capital, there have been just four biotech IPOs this year that have raised over $50 million — down from 10 in the same period last year. Venture bets are slowing too. Driving the news: Carlsmed, a personalized spine surgery company backed by B Capital Group and U.S. Venture Partners warned in its prospectus that "the current U.S. presidential administration" has issued policies to cut headcount and budgets in agencies including the FDA. "It remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA's ability to conduct routine activities," it continued. Sixth Street-backed cancer diagnostics company, Caris Life Sciences, which went public in late June, said this: "The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS, and related agencies," Caris' prospectus read. "These actions ... may propose policy changes that create additional uncertainty for our business. Zoom out: Though Carlsmed says it's "unclear the degree to which" the cuts will affect the FDA's ability to conduct routine activity, those in the space already feel the effects. The FDA told KalVista Pharmaceuticals last month that the agency would miss a deadline in approving a drug for potentially life-threatening genetic disorders — marking what appears to be the first time a review had to be extended over DOGE cuts. Verve Therapeutics, in a filing explaining its rationale for selling to Eli Lilly for $1.3 billion, noted that Peter Marks resignation in March as director of the FDA played a role in its move to sell rather than raise additional capital.
Bloomberg
2 days ago
- Business
- Bloomberg
AI-Surgical Firm Carlsmed Seeks to Raise $107.2 Million in IPO
Carlsmed Inc., a medical technology company that uses AI to personalize spine surgery, is seeking to raise as much as $107.2 million in a US initial public offering. The B Capital Group -backed firm plans to market 6.7 million shares for $14 to $16 each, according to its Tuesday filing with the US Securities and Exchange Commission.
Yahoo
2 days ago
- Business
- Yahoo
Carlsmed Announces Launch of Initial Public Offering
CARLSBAD, Calif., July 15, 2025--(BUSINESS WIRE)--Carlsmed, Inc. ("Carlsmed"), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the launch of its initial public offering of 6,700,000 shares of common stock. In addition, the underwriters will have a 30-day option to purchase up to 1,005,000 additional shares of common stock from Carlsmed at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is expected to be between $14.00 and $16.00 per share of common stock. Carlsmed has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol "CARL." BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are acting as joint lead book-running managers for the proposed offering. Truist Securities and BTIG are acting as joint book-runners for the proposed offering. The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by email at prospectus-ny@ or by phone number at (866) 471-2526; or Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1300, Minneapolis, Minnesota 55402, by email at prospectus@ or by telephone at (800) 747-3924. A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Carlsmed Carlsmed is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. View source version on Contacts Investor Relations Caroline Corner, PhDPartner ICR HealthcareIR@ Media Inquiries LeAnn BurtonSenior Director Brand MarketingLBurton@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 days ago
- Business
- Business Wire
Carlsmed Announces Launch of Initial Public Offering
CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. ('Carlsmed'), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the launch of its initial public offering of 6,700,000 shares of common stock. In addition, the underwriters will have a 30-day option to purchase up to 1,005,000 additional shares of common stock from Carlsmed at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is expected to be between $14.00 and $16.00 per share of common stock. Carlsmed has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol 'CARL.' BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are acting as joint lead book-running managers for the proposed offering. Truist Securities and BTIG are acting as joint book-runners for the proposed offering. The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by email at prospectus-ny@ or by phone number at (866) 471-2526; or Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1300, Minneapolis, Minnesota 55402, by email at prospectus@ or by telephone at (800) 747-3924. A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Carlsmed Carlsmed is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery.
Yahoo
27-06-2025
- Business
- Yahoo
Carlsmed targets IPO to continue medtech public listing boom
AI-focused spinal surgery firm Carlsmed is planning to go public, adding to a strong year of medtech initial public offerings (IPOs). Carlsmed filed a registration statement on Form S-1 with the US Securities and Exchange Commission (SEC) on 26 July, indicating its intention to go public. The form neither detailed how many shares the device maker is looking to sell nor the price range at which they will be sold, meaning it is not possible to calculate how much the IPO will raise. The Form S-1, used by companies when notifying the SEC of their intent to carry out public offerings, only mentioned that the listing would have occurred on the Nasdaq. Carlsmed has developed a personalised surgery platform called aprevo, which it claims enhances surgical outcomes, lowers the need for revision surgery, and improves long-term outcomes. The company's portfolio comprises implantable lumbar and cervical patient-specific interbody fusion devices and accompanying software. The company already has clearance from the US Food and Drug Administration (FDA) for its lumbar and cervical devices. Whilst its lumbar spine fusion surgery products are commercialised in the US, it expects to market the cervical devices next year. In its S-1 form, Carlsmed said it will pursue additional clearances for its platform throughout 2025. The California-based company estimates an addressable market of approximately $13.4bn for its aprevo platform in the US. Carlsmed's books have had strong growth – the company reported revenue of $27.2m in 2024, up 97.2% from 2023. The IPO will look to add cash resources for the spinal specialist, which already raised $52.5m in Series C financing in March 2024. Carlsmed is the latest medtech company in 2025 to target an IPO. Although it is notable for its AI-driven spinal surgery devices, the company is part of a broader trend of AI-focused medtechs going public. Artificial pancreas maker Beta Bionics raised $204m in a Nasdaq listing in January while wearable defibrillator maker Kestra closed an IPO worth $202m before deductions. The public listings reflect a stronger IPO landscape for medtech companies that have previously suffered in recent times. The first half of 2025 consolidates investor predictions made in December last year, who were optimistic about recovery. "Carlsmed targets IPO to continue medtech public listing boom" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
